SG11201804307WA - Therapeutic agent for liver disease containing stromal cells derived from adipose tissue and method for producing the same - Google Patents

Therapeutic agent for liver disease containing stromal cells derived from adipose tissue and method for producing the same

Info

Publication number
SG11201804307WA
SG11201804307WA SG11201804307WA SG11201804307WA SG11201804307WA SG 11201804307W A SG11201804307W A SG 11201804307WA SG 11201804307W A SG11201804307W A SG 11201804307WA SG 11201804307W A SG11201804307W A SG 11201804307WA SG 11201804307W A SG11201804307W A SG 11201804307WA
Authority
SG
Singapore
Prior art keywords
therapeutic agent
adipose tissue
cells derived
stromal cells
producing
Prior art date
Application number
SG11201804307WA
Inventor
Hayato Kurata
Hidenori Nonaka
Original Assignee
Rohto Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rohto Pharmaceutical Co Ltd filed Critical Rohto Pharmaceutical Co Ltd
Publication of SG11201804307WA publication Critical patent/SG11201804307WA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0667—Adipose-derived stem cells [ADSC]; Adipose stromal stem cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Developmental Biology & Embryology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

An object of the present invention is to provide a method for producing a therapeutic agent for liver diseases containing stromal cells derived from adipose tissue, which is excellent in convenience in preparation of a therapeutic agent while maintaining an excellent 5 therapeutic effect on the stromal cells derived from adipose tissue against liver diseases, and a therapeutic agent for liver diseases obtained by such a producing method. The present invention is directed to a therapeutic agent for liver diseases containing stromal cells derived from adipose tissue which has been subjected to both cryopreservation and thawing at least twice. 10
SG11201804307WA 2015-11-24 2016-11-17 Therapeutic agent for liver disease containing stromal cells derived from adipose tissue and method for producing the same SG11201804307WA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2015228731 2015-11-24
PCT/JP2016/084127 WO2017090509A1 (en) 2015-11-24 2016-11-17 Therapeutic agent for liver disease including adipose-tissue-derived stromal cells, and method for producing said therapeutic agent

Publications (1)

Publication Number Publication Date
SG11201804307WA true SG11201804307WA (en) 2018-06-28

Family

ID=58763527

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201804307WA SG11201804307WA (en) 2015-11-24 2016-11-17 Therapeutic agent for liver disease containing stromal cells derived from adipose tissue and method for producing the same

Country Status (7)

Country Link
US (1) US20180344775A1 (en)
EP (1) EP3381458B1 (en)
JP (1) JP7244991B2 (en)
CN (1) CN108289915A (en)
HK (1) HK1254380A1 (en)
SG (1) SG11201804307WA (en)
WO (1) WO2017090509A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2018116732A1 (en) * 2016-12-22 2019-10-24 ロート製薬株式会社 Non-alcoholic steatohepatitis therapeutic agent and non-alcoholic steatohepatitis treatment kit
CN110177871B (en) * 2017-03-03 2023-05-09 日本乐敦制药株式会社 Mesenchymal stem cell and therapeutic agent for liver disease
JPWO2023112942A1 (en) * 2021-12-16 2023-06-22

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6777231B1 (en) 1999-03-10 2004-08-17 The Regents Of The University Of California Adipose-derived stem cells and lattices
US20030054331A1 (en) 2001-09-14 2003-03-20 Stemsource, Inc. Preservation of non embryonic cells from non hematopoietic tissues
AU2002357135C1 (en) * 2001-12-07 2009-01-22 Macropore Biosurgery, Inc. Systems and methods for treating patients with processed lipoaspirate cells
ES2313805B1 (en) 2004-10-04 2009-12-23 Cellerix, S.L. IDENTIFICATION AND ISOLATION OF MULTIPOTENT CELLS OF NON-OSTEOCONDRAL MESENQUIMAL FABRIC.
EP2361970A1 (en) * 2004-09-24 2011-08-31 Angioblast Systems Incorporated Method of enhancing proliferation and/or survival of mesenchymal precursor cells (MPC)
WO2008140141A1 (en) * 2007-05-16 2008-11-20 Rnl Bio Co., Ltd. Pharmaceutical composition for preventing and treating liver fibrosis or hepatic cirrhosis comprising mesenchymal stem cell
JP2009001509A (en) * 2007-06-19 2009-01-08 Univ Nagoya Composition for regenerating tissue by using adipose tissue-originated stem cell
EP3338549A1 (en) * 2007-11-20 2018-06-27 Pioneer Surgical Orthobiologics, Inc. Cryopreservation of cells using cross-linked bioactive hydrogel matrix particles
US8481253B2 (en) * 2008-03-19 2013-07-09 Cryo-Save Ag Cryopreservation of adipose tissue for the isolation of mesenchymal stem cells
CA2768613A1 (en) 2009-07-20 2011-01-27 The General Hospital Corporation D/B/A Massachusetts General Hospital Methods and compositions for improving the viability of cryopreserved cells
AU2011249406B2 (en) 2010-05-06 2015-05-14 Stem Cell Medicine Ltd. Stem cell bank for personalized medicine
JP5804342B2 (en) * 2010-09-11 2015-11-04 国立大学法人金沢大学 Therapeutic agent for hepatitis including adipose tissue-derived stromal cells
ES2600321T3 (en) * 2011-08-04 2017-02-08 Ethianum Betriebsgesellschaft Mbh & Co. Kg Means for liver regeneration
SG10201606745XA (en) * 2011-09-23 2016-10-28 Cell Ideas Pty Ltd Therapeutics using adipose cells and cell secretions
CA2857545A1 (en) * 2011-11-30 2013-06-06 Advanced Cell Technology, Inc. Mesenchymal stromal cells and uses related thereto
DK2898064T3 (en) 2012-09-19 2019-03-04 Microvascular Tissues Inc COMPOSITIONS FOR TREATMENT AND PREVENTION OF TISSUE DAMAGE AND DISEASE
CN103451152A (en) * 2013-08-30 2013-12-18 浙江大学 Application of adipose-derived mesenchymal stem cells in preparation of liver cancer chemosensitization preparation
WO2016001839A1 (en) * 2014-06-30 2016-01-07 Stempeutics Research Pvt. Ltd. Management of liver disease using pooled mesenchymal stromal cells
TWI740812B (en) * 2015-01-05 2021-10-01 國立陽明大學 Mesenchymal stem cells for treating liver diseases

Also Published As

Publication number Publication date
CN108289915A (en) 2018-07-17
EP3381458C0 (en) 2023-06-07
US20180344775A1 (en) 2018-12-06
EP3381458A1 (en) 2018-10-03
WO2017090509A1 (en) 2017-06-01
JP7244991B2 (en) 2023-03-23
EP3381458B1 (en) 2023-06-07
JPWO2017090509A1 (en) 2018-09-06
HK1254380A1 (en) 2019-07-19
EP3381458A4 (en) 2019-07-24

Similar Documents

Publication Publication Date Title
PH12017501956A1 (en) Compositions of obeticholic acid and methods of use
MX2019002356A (en) Biaryl compounds useful as immunomodulators.
MX2017013562A (en) Microbiome regulators and related uses thereof.
MX2021007268A (en) Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl] amino}acetic acid, compositions, and uses thereof.
MX2020001757A (en) Compounds, salts thereof and methods for treatment of diseases.
MX2016002544A (en) Compounds useful as immunomodulators.
PH12015502649A1 (en) Heterocyclic compounds as pest control agents
PH12018502056A1 (en) Methods of treatment of cholestatic diseases
MX2016016143A (en) Substituted [1,2,4]triazole compounds.
MX2017009417A (en) Solid forms of 2-(5-(3-fluorophenyl)-3-hydroxypicolinamido)acetic acid, compositions, and uses thereof.
MY186547A (en) 4?-fluoro-2?-methyl substituted nucleoside derivatives
MX2017005861A (en) Methods to target transcriptional control at super-enhancer regions.
MX368903B (en) THERAPEUTIC COMPOUNDS and USES THEREOF.
MY192425A (en) Polymorphs
BR112018003526A2 (en) methods of treating inflammatory diseases
PH12017500737A1 (en) Kcnq2-5 channel activator
MX2022006817A (en) Formulations/compositions comprising a btk inhibitor.
MY180844A (en) Solid pharmaceutical compositions comprising biopterin derivatives and uses of such compositions
EA033342B1 (en) Pyrrolidine carboxamido derivatives and methods for preparing and using the same
MX2018005987A (en) Heterocyclic compounds for the treatment of disease.
SG11201804307WA (en) Therapeutic agent for liver disease containing stromal cells derived from adipose tissue and method for producing the same
MX2019000677A (en) B-cell-mimetic cells.
PH12016501326A1 (en) (s)-3'-methyl-abscisic acid and esters thereof
PH12017501693A1 (en) Compositions for the treatment of kidney and/or liver diseases
PH12017500173A1 (en) Post-harvest disease control agent and post-harvest disease control method